Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

678 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer.
Iwamoto S, Maeda H, Hazama S, Oba K, Okayama N, Suehiro Y, Yamasaki T, Suzuki N, Nagano H, Sakamoto J, Mishima H, Nagata N. Iwamoto S, et al. Among authors: mishima h. J Cancer. 2018 Oct 18;9(22):4092-4098. doi: 10.7150/jca.26840. eCollection 2018. J Cancer. 2018. PMID: 30519308 Free PMC article.
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Kato T, Mishima H, Ikenaga M, Murata K, Ishida H, Fukunaga M, Ota H, Tominaga S, Ohnishi T, Amano M, Ikeda K, Ikeda M, Sekimoto M, Sakamoto J, Monden M. Kato T, et al. Among authors: mishima h. Cancer Chemother Pharmacol. 2008 Feb;61(2):275-81. doi: 10.1007/s00280-007-0471-2. Epub 2007 Apr 11. Cancer Chemother Pharmacol. 2008. PMID: 17429630 Clinical Trial.
The importance of evaluation of DNA amplificability in KRAS mutation testing with dideoxy sequencing using formalin-fixed and paraffin-embedded colorectal cancer tissues.
Okayama N, Nishioka M, Hazama S, Sakai K, Suehiro Y, Maekawa M, Sakamoto J, Iwamoto S, Kato T, Mishima H, Oka M, Hinoda Y. Okayama N, et al. Among authors: mishima h. Jpn J Clin Oncol. 2011 Feb;41(2):165-71. doi: 10.1093/jjco/hyq173. Epub 2010 Oct 5. Jpn J Clin Oncol. 2011. PMID: 20926413
FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase III study (EAGLE Study).
Mishima H, Oba K, Sakamoto J, Muro K, Yoshino T, Hyodo I, Maehara Y. Mishima H, et al. Jpn J Clin Oncol. 2012 Feb;42(2):134-8. doi: 10.1093/jjco/hyr180. Epub 2011 Dec 12. Jpn J Clin Oncol. 2012. PMID: 22167662 Free PMC article. Clinical Trial.
Is there diversity among UGT1A1 polymorphism in Japan?
Kobayashi M, Hazama S, Takahashi K, Oba K, Okayama N, Nishioka M, Hinoda Y, Oka M, Okamoto K, Maeda H, Nakamura D, Sakamoto J, Mishima H. Kobayashi M, et al. Among authors: mishima h. World J Gastrointest Oncol. 2012 Jul 15;4(7):170-5. doi: 10.4251/wjgo.v4.i7.170. World J Gastrointest Oncol. 2012. PMID: 22848786 Free PMC article.
678 results